Efficacy and safety of tigecycline: a systematic review and meta-analysis (Q37891606)

24 August 2017

0 references

1 reference

title

Efficacy and safety of tigecycline: a systematic review and meta-analysis (English)

1 reference

24 August 2017

0 references

1 reference

4

Leonard Leibovici

1 reference

24 August 2017

3

Mical Paul

1 reference

24 August 2017

1

Dafna Yahav

1 reference

24 August 2017

2

Adi Lador

1 reference

PubMed ID

21685488

24 August 2017

language of work or name

English

0 references

publication date

18 June 2011

1 reference

Journal of Antimicrobial Chemotherapy

24 August 2017

9

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

24 August 2017

66

1 reference

24 August 2017

9

1 reference

24 August 2017

1963-1971

1 reference

Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America

24 August 2017

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR242

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR242

In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR242

Tigecycline: a new glycylcycline for treatment of serious infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR242

A review of tigecycline--the first glycylcycline

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR242

Tigecycline-induced acute pancreatitis: case report and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR242

Severe coagulation disorder with hypofibrinogenemia associated with the use of tigecycline

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR242

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR242

Tigecycline for the treatment of patients with community-acquired pneumonia requiring hospitalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR242

A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR242

In vitro activity of tigecycline against patient isolates collected during phase 3 clinical trials for diabetic foot infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR242

Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR242

Tigecycline versus levofloxacin for the treatment of community-acquired pneumonia: European experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR242

The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR242

Efficacy and safety of tigecycline monotherapy compared with vancomycin-aztreonam in the treatment of complicated skin and skin structure infections in patients from India and Taiwan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR242

Overview of tigecycline efficacy and safety in the treatment of complicated skin and skin structure infections - a European perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR242

The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR242

The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections - the European experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR242

Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR242

Predictors of efficacy and health resource utilization in treatment of complicated intra-abdominal infections: evidence for pooled clinical studies comparing tigecycline with imipenem-cilastatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR242

Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR242

Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR242

Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR242

Efficacy and safety of tigecycline monotherapy vs. imipenem/cilastatin in Chinese patients with complicated intra-abdominal infections: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR242

Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR242

Tigecycline is efficacious in the treatment of complicated intra-abdominal infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR242

Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR242

A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744].

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR242

Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR242

Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR242

A multicentre, open-label, randomized comparative study of tigecycline versus ceftriaxone sodium plus metronidazole for the treatment of hospitalized subjects with complicated intra-abdominal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR242

Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR242

Safety and efficacy of intravenous tigecycline in subjects with secondary bacteremia: pooled results from 8 phase III clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR242

Tigecycline possibly underdosed for the treatment of pneumonia: a pharmacokinetic viewpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR242

Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR242

A sensitive human bone assay for quantitation of tigecycline using LC/MS/MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR242

Superinfection during treatment of nosocomial infections with tigecycline.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR242

Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR242

Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR242

A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR242

Tigecycline for treatment of severe infections in intensive care: a drug use evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR242

Tigecycline for the treatment of patients with severe sepsis or septic shock: a drug use evaluation in a surgical intensive care unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR242

Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR242

Outcome reporting among drug trials registered in ClinicalTrials.gov

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR242

21 January 2018

Identifiers

DOI

10.1093/JAC/DKR242

1 reference

24 August 2017

1 reference

PubMed ID

21685488